iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,882 shares of iTeos Therapeutics stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $10.21, for a total value of $448,035.22. Following the completion of the transaction, the chief executive officer now owns 135,903 shares in the company, valued at $1,387,569.63. The trade was a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Michel Detheux also recently made the following trade(s):
- On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total value of $85,764.00.
- On Wednesday, June 4th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $443,218.30.
- On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total transaction of $84,840.00.
iTeos Therapeutics Price Performance
Shares of iTeos Therapeutics stock traded down $0.01 during midday trading on Friday, hitting $10.17. 1,062,628 shares of the company were exchanged, compared to its average volume of 658,136. The firm has a 50 day simple moving average of $7.38 and a 200-day simple moving average of $7.47. The firm has a market cap of $389.25 million, a P/E ratio of -3.23 and a beta of 1.39. iTeos Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $18.13.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14. Equities research analysts expect that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.
Institutional Trading of iTeos Therapeutics
Several large investors have recently added to or reduced their stakes in ITOS. Strs Ohio acquired a new position in shares of iTeos Therapeutics in the 1st quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new position in iTeos Therapeutics in the 4th quarter valued at $42,000. CWM LLC boosted its stake in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after purchasing an additional 6,936 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after purchasing an additional 3,293 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of iTeos Therapeutics in the first quarter valued at $65,000. 97.16% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently commented on ITOS. Piper Sandler reiterated an "overweight" rating and set a $12.00 target price (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Wedbush cut iTeos Therapeutics from an "outperform" rating to a "neutral" rating and upped their price target for the company from $10.00 to $12.00 in a report on Wednesday, May 28th. Leerink Partnrs lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. Finally, Leerink Partners restated a "market perform" rating and set a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $15.86.
Check Out Our Latest Research Report on ITOS
About iTeos Therapeutics
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
